Market analysis
Osteosarcoma is a kind of bone tumor in which there is a multiplication of osteoblasts. It is one the basic kind of malignant growth prompting the growth of immature bones. The tumor is mostly seen happening in children and adolescents. It is more prevalent in males than females. Juxtacortical osteosarcoma, Intramedullary osteosarcoma, and extraskeletal osteosarcoma are the three kinds of osteosarcomas, among which intramedullary osteosarcoma is the most predominant one. The growing prevalence of the osteosarcoma among the children and teenagers along with the rising demand for the better treatment initiatives are one of the key drivers responsible for the growth of the global osteosarcoma market during the forecast period. The global osteosarcoma market is anticipated to grow at a CAGR of 6.40% during the forecast period (2017-2023).

Market Segmentation
The global osteosarcoma market is divided on the basis of its types, treatment, diagnosis, end user and regional demand. Based on its types, the market is segmented into juxtacortical osteosarcoma, intramedullary osteosarcoma, and extra-skeletal osteosarcoma. Based on its treatment, the market is categorized into chemotherapy, radiation therapy, surgery, among others. On the basis of its diagnosis, the market is bifurcated into biopsy, bone scan, MRI, X-ray, CT Scan, and others. On the basis of its end user, the global market is classified into cancer research centers, hospitals & clinics, and others.

Regional analysis
Geographically, the global osteosarcoma market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.

Major players
Some of the major players in the global osteosarcoma market include companies like Hikma Pharmaceuticals (U.K), Baxter (U.S.), Advaxis Inc., Pfizer (U.S.), Novartis (U.S.), Spectrum Pharmaceuticals, Inc. (U.S.), Isofol Medical AB (Sweden), Bellicum Pharmaceuticals (U.S.), among others.